Publications

Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma.

Authors: CA Rebbeck, J Xian, S Bornelöv, J Geradts, A Hobeika, H Geiger, JF Alvarez...

E-pub date: 13 Jun 2022

Journal name: Nat Commun

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

Authors: RC Coombes, PD Badman, JP Lozano-Kuehne, X Liu, IR Macpherson, I Zubairi, R...

E-pub date: 10 Jun 2022

Journal name: Nat Commun

Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant.

Authors: L Correia, R Magno, JM Xavier, BP de Almeida, I Duarte, F Esteves, M Ghezzo...

E-pub date: 8 Jun 2022

Journal name: NPJ Breast Cancer

A pan-cancer compendium of chromosomal instability.

Authors: RM Drews, B Hernando, M Tarabichi, K Haase, T Lesluyes, PS Smith, L Morrill...

Research group: Markowetz Group

E-pub date: 1 Jun 2022

Journal name: Nature

The development of infrastructure for mainstream ovarian cancer genetic testing (DEMO)

Authors: IG Funingana, E Leung, M-L Alcaraz, L Bird, JE Ang, C Parkinson, M Jimenez-...

E-pub date: 1 Jun 2022

Journal name: Annals of Oncology

Real-world whole sequencing data of ovarian cancer patients

Authors: IG Funingana, J Ambrose, K Hosking, N Demiris, A Sosinsky, JD Brenton

E-pub date: 1 Jun 2022

Journal name: Annals of Oncology

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.

Authors: F Orlando, A Romanel, B Trujillo, M Sigouros, D Wetterskog, O Quaini, G Leo...

E-pub date: 1 Jun 2022

Journal name: NAR Cancer

The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer.

Authors: SA Patel, S Hirosue, P Rodrigues, E Vojtasova, EK Richardson, J Ge, SE Syaf...

E-pub date: 1 Jun 2022

Journal name: Nature

Filters

Research Groups

Core Facilities

Start date

End date

Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma.

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant.

A pan-cancer compendium of chromosomal instability.

The development of infrastructure for mainstream ovarian cancer genetic testing (DEMO)

Real-world whole sequencing data of ovarian cancer patients

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.

The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer.

Themes

Filters

Research Groups

Core Facilities

Start date

End date

Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma.

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant.

A pan-cancer compendium of chromosomal instability.

The development of infrastructure for mainstream ovarian cancer genetic testing (DEMO)

Real-world whole sequencing data of ovarian cancer patients

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.

The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer.